XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

Schedule of Disaggregation of Revenue

Primary geographical markets		2022				2021				2022				2021
In thousands of US dollars ($)		Three Months Ended September 30,								Nine Months Ended September 30,
Primary geographical markets		2022				2021				2022				2021
North America		$	138			$	351			$	709			$	1,036
Europe			13				57				61				244
Asia			(7	)			110				352				407
		$	144			$	518			$	1,122			$	1,687

Major products/services lines		2022				2021				2022				2021
In thousands of US dollars ($)		Three Months Ended September 30,								Nine Months Ended September 30,
Major products/services lines		2022				2021				2022				2021
Hardware		$	1			$	276			$	532			$	989
Consumables			49				45				165				191
Contract research services			-				100				125				242
Sample preparation accessories			41				39				93				108
Technical support/extended service contracts			41				26				94				84
Agrochem Products			10				17				93				17
Shipping and handling			2				11				20				46
Other			-				4				-				10
Revenue		$	144			$	518			$	1,122			$	1,687

1		2022				2021				2022				2021
In thousands of US dollars ($)		Three Months Ended September 30,								Nine Months Ended September 30,
Timing of revenue recognition		2022				2021				2022				2021
Products transferred at a point in time		$	103			$	392			$	903			$	1,361
Services transferred over time			41				126				219				326
Revenue		$	144			$	518			$	1,122			$	1,687

Schedule of Contract Balances

Contract balances

Schedule of Contract Balances

		1				2
In thousands of US dollars ($)		September 30, 2022				December 31, 2021
Receivables, which are included in ‘Accounts Receivable’		$	166			$	155
Contract liabilities (deferred revenue)			127				41

Schedule of Future Related to Performance Obligations

In thousands of US dollars ($)		2022				2023				Total
Extended warranty service		$	32			$	95			$	127

Schedule of Customer Concentration Risk Percentage

The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2022 and 2021.

		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2022				2021				2022				2021
Top Five Customers			42	%			56	%			31	%			42	%
Federal Agencies			4	%			3	%			1	%			6	%

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable.

		September 30, 2022				December 31, 2021
Top Five Customers			84	%			82	%
Federal Agencies			0	%			5	%

Schedule of Computation of Loss Per Share

The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2022 and 2021:

		2022				2021				2022				2021
		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2022				2021				2022				2021
Numerator:
Net loss attributable to common stockholders		$	(4,893,946	)		$	(6,199,176	)		$	(12,913,826	)		$	(18,387,204	)

Denominator for basic and diluted loss per share:
Weighted average common stock shares outstanding			11,131,742				7,561,728				10,429,817				6,083,017

Loss per common share – basic and diluted		$	(0.44	)		$	(0.82	)		$	(1.24	)		$	(3.02	)

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

		2022				2021
		As of September 30,
		2022				2021
Stock options			1,307,822				1,342,490
Convertible debt			6,471,034				5,330,318
Common stock warrants			16,293,768				16,265,570
Convertible preferred stock:
Series D Convertible Preferred Stock			25,000				25,000
Series G Convertible Preferred Stock			26,857				26,857
Series H Convertible Preferred Stock			33,334				33,334
Series H2 Convertible Preferred Stock			70,000				70,000
Series J Convertible Preferred Stock			115,267				115,267
Series K Convertible Preferred Stock			229,334				229,334
Series AA Convertible Preferred Stock			8,645,000				8,649,000
Total potentially dilutive shares			33,217,416				32,087,170

Schedule of Stock Based Compensation Expense

		2022				2021				2022				2021
		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2022				2021				2022				2021
Cost of sales		$	2,184			$	8,664			$	8,694			$	18,824
Research and development			9,499				43,031				37,803				95,384
Selling and marketing			4,583				7,168				18,166				17,650
General and administrative			16,161				36,385				64,321				88,085
Total stock-based compensation expense		$	32,427			$	95,248			$	128,984			$	219,943

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2022:

						Fair value measurements at September 30, 2022 using:
		September 30, 2022				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
Equity Securities		$	51,929			$	51,929				-				-
Total Financial Assets		$	51,929			$	51,929			$	-			$	-

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021:

						Fair value measurements at December 31, 2021 using:
		December 31, 2021				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
Equity Securities			59,976				59,976				-				-
Total Financial Assets		$	59,976			$	59,976			$	-			$	-

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details